HUTCHMED (00013.HK): Key Phase II Data of Fisogatinib to Be Presented at ESMO Gastrointestinal Cancers Congress

NewTimeSpace News: On June 25, 2026, HUTCHMED (00013.HK) issued a voluntary announcement stating that pivotal Phase II registrational study outcomes of fisogatinib in patients with FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma will be presented as a rapid oral presentation at the ESMO Gastrointestinal Cancers Congress held in Munich, Germany from July 1 to 4, 2026.

Per the announcement, the study met its primary endpoint. The objective response rate assessed by an independent review committee stood at 42.5% (95% CI: 30.0%-53.6%), with a disease control rate of 83.9%, median duration of response of 6.9 months, median progression-free survival of 6.9 months, and median overall survival of 16.6 months.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.